Why Rein Therapeutics Inc.’s (RNTX) Stock Is Up 5.86%
As of Thursday, September 03, Rein Therapeutics Inc.’s RNTX share price has surged by 5.86%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company’s lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company’s pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel, which is in preclinical trial phase for the treatment of cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas.
Commentary & Analysis
Why Rein Therapeutics Inc.’s (RNTX) Stock Is Up 8.44%
As of Thursday, September 03, Rein Therapeutics Inc.’s RNTX share price has surged by 8.44%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Rein Therapeutics Inc.’s (RNTX) Stock Is Up 9.37%
As of Thursday, September 03, Rein Therapeutics Inc.’s RNTX share price has surged by 9.37%, which has investors questioning if this is right time to sell.Michael Rose
Why Rein Therapeutics Inc.’s (RNTX) Stock Is Up 5.14%
As of Wednesday, August 19, Rein Therapeutics Inc.’s RNTX share price has surged by 5.14%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Rein Therapeutics Inc.’s (RNTX) Stock Is Up 6.01%
As of Tuesday, August 04, Rein Therapeutics Inc.’s RNTX share price has surged by 6.01%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | RNTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $67.1 | $288.9 | 18% |
|
| Shares Out (Mil) | 67.1 | 54.0 | 54% |
|
| Institutional Ownership | 84.9% | 93.1% | 53% |
|
| Float (Mil) | 65.8 | 41.4 | 53% |
|
| Beta | 1.37 | 0.94 | 78% |
|
| Avg Daily Volume (000s) | 589 | 480 | 62% |
|
| Price Change (52-week) |
(42.4%) | 59.9% | 18% |
|
| Growth | RNTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (18.7%) | (10.1%) | 21% |
|
| EPS (5yr) | 30.6% | 15.9% | 82 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (18.9%) | (15.6%) | 36% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | RNTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($50) | ($43) | 16% |
|
| EPS (TTM) | ($1.298) | ($1.500) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | ($19) | ($31) | 15% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $75 | $190 | 19% |
|
| Valuation | RNTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.48 | 2.84 | 84% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | RNTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (80.6%) | (47.7%) | 7% |
|
| ROE | (753.6%) | (55.0%) | 0% |
|
| Liabilities to Assets | 16.3% | 29.6% | 10% |
|
| F-Score | 2 | 3 | 7% |
|
Rein Therapeutics Inc. did not pass any screens on 9/2/2026.
